Clinical Trial

Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases

Study acronym: NeoSRS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the local control rate on the target lesion at 6, 12, and 24 months after treatment with neoadjuvant stereotactic radiotherapy (SRS NEO group) compared to standard care, adjuvant stereotactic radiotherapy (POST OP SRS group).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-02-23; most recent amendment 2026-06-12.
Trial Details
NCT Number NCT07437820
Lead Sponsor GCS Ramsay Santé pour l'Enseignement et la Recherche
Collaborators: Euraxi Pharma
Conditions Brain Metastases, Adult
Enrollment 68 participants
Start Date 2026-07
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15